Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.
Also called NCT01681095
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 110 participants
- Sponsor
- Marc Sakwa, MD
- Registry
-
NCT01681095
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01681095. Randomized; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2017-03-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
- Condition
- Coronary Artery Disease
- Condition
- Myocardial Ischemia
- Condition
- Coronary Disease
- Condition
- Heart Diseases
- Condition
- Valvular Heart Disease
- Intervention (Drug)
- Custodiol HTK
- Intervention (Drug)
- Cold Blood Cardioplegia
- Lead sponsor
- Marc Sakwa, MD
- Collaborator
- Essential Pharmaceuticals, LLC
Record details
- Record id
cardio:ct-nct01681095- Content hash
039921d7631cd23ce9377b9206010e9f66bec0780e9c8fd02cd66f475c2bc443